OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Showing 25 citing articles:
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature
Yan-Kun Chen, Tingting Liu, Farah Khameis Farag Teia, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 23
Yan-Kun Chen, Tingting Liu, Farah Khameis Farag Teia, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 23
Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies
Sihua Wang, Sheng Wang, Yan Wang, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 2, pp. 497-519
Open Access | Times Cited: 8
Sihua Wang, Sheng Wang, Yan Wang, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 2, pp. 497-519
Open Access | Times Cited: 8
Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study
Kamel Mohammedi, Narimène Belhatem, Tina Landsvig Berentzen, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1855-1864
Open Access | Times Cited: 15
Kamel Mohammedi, Narimène Belhatem, Tina Landsvig Berentzen, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1855-1864
Open Access | Times Cited: 15
Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes
Caroline Swift, Monica Frazer, Andrew Sargent, et al.
Clinical Therapeutics (2025)
Open Access
Caroline Swift, Monica Frazer, Andrew Sargent, et al.
Clinical Therapeutics (2025)
Open Access
Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study
Cesare Berra, Roberto Manfrini, Francesco Bifari, et al.
Pharmacological Research (2025) Vol. 213, pp. 107640-107640
Open Access
Cesare Berra, Roberto Manfrini, Francesco Bifari, et al.
Pharmacological Research (2025) Vol. 213, pp. 107640-107640
Open Access
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Roberta Manti, Salvatore De Cosmo, Paolo Desenzani, et al.
Diabetes Therapy (2025)
Open Access
Roberta Manti, Salvatore De Cosmo, Paolo Desenzani, et al.
Diabetes Therapy (2025)
Open Access
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
JAMES AMAMOO, Riddhi Doshi, Joshua Noone, et al.
Diabetes Therapy (2025)
Open Access
JAMES AMAMOO, Riddhi Doshi, Joshua Noone, et al.
Diabetes Therapy (2025)
Open Access
Long‐Term Effectiveness of Once‐Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real‐World Study
Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 4
Open Access
Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 4
Open Access
Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE -2 study
Cesare Berra, Roberto Manfrini, Francesco Bifari, et al.
Pharmacological Research (2024) Vol. 210, pp. 107517-107517
Open Access | Times Cited: 3
Cesare Berra, Roberto Manfrini, Francesco Bifari, et al.
Pharmacological Research (2024) Vol. 210, pp. 107517-107517
Open Access | Times Cited: 3
Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide
Ametov As, И. Е. Шохин, E. A. Rogozhina, et al.
Pharmacy & Pharmacology (2024) Vol. 11, Iss. 4, pp. 324-346
Open Access | Times Cited: 1
Ametov As, И. Е. Шохин, E. A. Rogozhina, et al.
Pharmacy & Pharmacology (2024) Vol. 11, Iss. 4, pp. 324-346
Open Access | Times Cited: 1
Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study
Dagoberto Serpa-Díaz, Carlos A Llanos-Florez, Ronald Andrés Serrano Uribe, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 6, pp. 1451-1460
Open Access | Times Cited: 1
Dagoberto Serpa-Díaz, Carlos A Llanos-Florez, Ronald Andrés Serrano Uribe, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 6, pp. 1451-1460
Open Access | Times Cited: 1
Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
Irene Caballero Mateos, María Dolores García de Lucas, Viyey Doulatram‐Gamgaram, et al.
Nutrients (2024) Vol. 16, Iss. 15, pp. 2545-2545
Open Access | Times Cited: 1
Irene Caballero Mateos, María Dolores García de Lucas, Viyey Doulatram‐Gamgaram, et al.
Nutrients (2024) Vol. 16, Iss. 15, pp. 2545-2545
Open Access | Times Cited: 1
Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
Jean‐François Yale, Atheline Major‐Pedersen, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4429-4440
Closed Access | Times Cited: 1
Jean‐François Yale, Atheline Major‐Pedersen, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4429-4440
Closed Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis
Gottfried Rudofsky, Markus Menzen, Louis Potier, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 788-800
Open Access | Times Cited: 1
Gottfried Rudofsky, Markus Menzen, Louis Potier, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 788-800
Open Access | Times Cited: 1
Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study
Ying Hu, Xianwen Chen, Huimin Zou, et al.
Advances in Therapy (2024)
Closed Access | Times Cited: 1
Ying Hu, Xianwen Chen, Huimin Zou, et al.
Advances in Therapy (2024)
Closed Access | Times Cited: 1
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
María Dolores García de Lucas, Irene Caballero, José Carlos Fernández‐García, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
María Dolores García de Lucas, Irene Caballero, José Carlos Fernández‐García, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes
Monica Frazer, Caroline Swift, Andrew Sargent, et al.
Journal of Diabetes & Metabolic Disorders (2023) Vol. 23, Iss. 1, pp. 727-737
Open Access | Times Cited: 3
Monica Frazer, Caroline Swift, Andrew Sargent, et al.
Journal of Diabetes & Metabolic Disorders (2023) Vol. 23, Iss. 1, pp. 727-737
Open Access | Times Cited: 3
The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide
Peter Kurtzhals, Frederik Flindt Kreiner, Rubdeep Singh Bindra
Diabetes Research and Clinical Practice (2023) Vol. 203, pp. 110881-110881
Open Access | Times Cited: 2
Peter Kurtzhals, Frederik Flindt Kreiner, Rubdeep Singh Bindra
Diabetes Research and Clinical Practice (2023) Vol. 203, pp. 110881-110881
Open Access | Times Cited: 2
Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia
Daisy C. Buenaventura-Collazos, Andrés Felipe García Ramos, Carlos Mario Balcázar Valencia, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Daisy C. Buenaventura-Collazos, Andrés Felipe García Ramos, Carlos Mario Balcázar Valencia, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Semaglutide for the management of diabesity: The real-world experience
Mohammed Alkhalifah, Hafsa Afsar, Anindya Shams, et al.
World Journal of Methodology (2024) Vol. 14, Iss. 3
Open Access
Mohammed Alkhalifah, Hafsa Afsar, Anindya Shams, et al.
World Journal of Methodology (2024) Vol. 14, Iss. 3
Open Access
Real-world Use of Oral Semaglutide in Patients with Type 2 Diabetes in India: A Retrospective Study
Sachin Chittawar, Sandeep Suri, Arpit Garg, et al.
International Journal of Diabetes and Technology (2024) Vol. 3, Iss. 4, pp. 159-164
Closed Access
Sachin Chittawar, Sandeep Suri, Arpit Garg, et al.
International Journal of Diabetes and Technology (2024) Vol. 3, Iss. 4, pp. 159-164
Closed Access
Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study
Tatjana Milenkovikj, Biljana Chekorova Mitreva, Sasha Jovanovska Mishevska, et al.
Diabetes Research and Clinical Practice (2023) Vol. 206, pp. 111018-111018
Open Access | Times Cited: 1
Tatjana Milenkovikj, Biljana Chekorova Mitreva, Sasha Jovanovska Mishevska, et al.
Diabetes Research and Clinical Practice (2023) Vol. 206, pp. 111018-111018
Open Access | Times Cited: 1
Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP–4i) in US Adults with Type 2 Diabetes
Xi Tan, Yuanjie Liang, Cory Gamble, et al.
Diabetes Therapy (2023) Vol. 15, Iss. 2, pp. 427-445
Open Access | Times Cited: 1
Xi Tan, Yuanjie Liang, Cory Gamble, et al.
Diabetes Therapy (2023) Vol. 15, Iss. 2, pp. 427-445
Open Access | Times Cited: 1
Weight Loss of Semaglutide Treatment for Patients With Overweight or Obesity: A Retrospective Observational Study in China
Xin-Hao Zhang, Ai-Xin Wu, Zhicheng Yang, et al.
Research Square (Research Square) (2023)
Open Access
Xin-Hao Zhang, Ai-Xin Wu, Zhicheng Yang, et al.
Research Square (Research Square) (2023)
Open Access
